Gene · 51185
CRBN: cereblon
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CRBN: cereblon. Genes, record 51185. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/51185
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q96SW2 | Protein cereblon | 442 | 98 | Ensembl, GeneID, HGNC |
Source UniProt
Patents63
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026523243 A | 2026-07-13 | 127 | Q96SW2 | Espacenet |
| JP 2026516229 A | 2026-05-20 | 127 | Q96SW2 | Espacenet |
| EP 4705323 A1 | 2026-03-11 | 127 | Q96SW2 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 40919 | Q96SW2 | Espacenet |
| WO 2025244125 A | 2025-11-27 | 23 | Q96SW2 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 820 | Q96SW2 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 582 | Q96SW2 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 582 | Q96SW2 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 820 | Q96SW2 | Espacenet |
| WO 2025068704 A1 | 2025-04-03 | 1 | Q96SW2 | Espacenet |
1 to 10 of 63
See all 63 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| IBERDOMIDE | CHEMBL3989927 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| LENALIDOMIDE | CHEMBL848 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
| LENALIDOMIDE | CHEMBL848 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE | CHEMBL6068337 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| POMALIDOMIDE | CHEMBL43452 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
| THALIDOMIDE | CHEMBL468 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
Trials1,695
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | IBERDOMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | LENALIDOMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07585747 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07569757 | POMALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07562022 | LENALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07555938 | POMALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07532525 | POMALIDOMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT07523737 | POMALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07505849 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 1,695
See all 1,695 trialsNIH grants1,407
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CRBN papers | Newest fiscal year |
|---|---|---|---|
| R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 28 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 27 | 2025 |
| R35CA197589 | Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities | 27 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 25 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 25 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 24 | 2025 |
| R01CA218278 | Degrading therapeutically important kinases using small molecules | 20 | 2025 |
| P01CA155258 | Integrative Oncogenomics of Multiple Myeloma | 15 | 2025 |
| R01CA240981 | Harnessing E3 Ligases for Cancer Therapy | 14 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 11 | 2025 |
1 to 10 of 1,407Source NIH's project files
See all 1,407 nih grantsPapers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PROTAC probe-assisted degradomics identifies SPINT2 as a candidate cellular target involved in the anti-cancer activity of Flupentixol. | Bioorg Chem | 2026 | 42826660 | PubTator, text mining | PubMed |
| A scalable, high-throughput glue perturbation screening platform for molecular glue discovery. | iScience | 2026 | 42824958 | PubTator, text mining | PubMed |
| Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma. | Cancer J | 2026 | 42809693 | PubTator, text mining | PubMed |
| Optimizing CRBN-ligands for optical targeted protein degradation. | RSC Med Chem | 2026 | 42807851 | PubTator, text mining | PubMed |
| Bridging E3 Ligase Binding and Targeted Degradation Through Fluorescence Polarization. | Int J Mol Sci | 2026 | 42794484 | PubTator, text mining | PubMed |
| Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers. | Bioorg Med Chem | 2026 | 42772077 | PubTator, text mining | PubMed |
| Molecular glues: Recent advances in cereblon substrate identification and mechanistic insights. | Smart Mol | 2026 | 42770064 | PubTator, text mining | PubMed |
| PARP1-targeting PROTAC attenuates alcohol-associated liver injury and ileal epithelial damage. | Biochem Pharmacol | 2026 | 42753829 | PubTator, text mining | PubMed |
| Design, Synthesis, Biological Studies and Putative Binding Mode of Novel Benzotriazolothalidomide Derivatives as Cereblon Ligands. | Chem Biol Drug Des | 2026 | 42740472 | PubTator, text mining | PubMed |
| Expanding the E3 Ligase Landscape: From Small Molecule to Biological Targeted Protein Degradation. | Handb Exp Pharmacol | 2026 | 42730806 | PubTator, text mining | PubMed |
1 to 10 of 2,935
See all 2,935 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/51185
GET https://conductscience.org/api/genes/v1/51185/patents?page=2